On June 24 and 25, 2015, the fifth and sixth subjects were enrolled in our ongoing Israeli study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study will treat up to 10 subjects with chronic, treatment-resistant PTSD from any cause. This study is actively seeking Israeli participants. “We are excited about the recent enrollments in our ongoing Israeli study, where we are getting promising results in a population with endemic trauma,” reports MAPS Clinical Research Scientist Berra Yazar-Klosinski, Ph.D.
